Form 4 Sage Therapeutics, Inc. For: Apr 17 Filed by: STARR KEVIN P
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC
April 23, 2018 10:20 AM EDTRBC Capital analyst Brian Abrahams sees weakness in Sage Therapeutics (NASDAQ: SAGE) on Friday, related to insider selling and a deal with Biogen for IONS, as a buying opportunity.
"... we view these as non-fundamental, and Friday's detailed, in-line brexanolone data, today's on-track NDA filing,... More
